Skip to main content

Table 1 List of immunohistochemical antibodies and their results

From: Primary mucinous ovarian tumors vs. ovarian metastases from gastrointestinal tract, pancreas and biliary tree: a review of current problematics

 

Mucinous ovarian (all)

MC

APE

CRC

Pancreas

Pancreatobiliary

Gastric

 

No. positive (all, %)

No. positive (3+, %)

No. positive (all, %)

No. positive (3+, %)

No. positive (all, %)

No. positive (3+, %)

No. positive (all, %)

No. positive (3+, %)

No. positive (all, %)

No. positive (3+, %)

No. positive (all, %)

No. positive (3+, %)

No. positive (all, %)

No. positive (3+, %)

SATB2

7.2

6.3

8.4

6.4

87

85.1

74.8

76.4

0

NA

0

NA

4.3

NA

CDX2

48.8

22.1

46

25.5

96.6

92.8

93.2

82.1

18.9

NA

31.2

28.6

62.8

17.4

CK7

89.9

86.5

90.3

87.8

26.2

13.3

30.9

5.6

95.1

90

95.5

82.8

67.2

66.7

CK20

68.3

37.1

64.7

40.6

92

77.7

89.8

74.1

57.3

14.3

55.2

22.2

67.6

53.6

ß-catenin

5.8

NA

7.9

NA

NA

NA

57

NA

NA

NA

11.8

NA

20

NA

MUC1

51

13.8

73.7

31.6

NA

NA

39.4

NA

92.2

NA

90.4

NA

54.2

NA

MUC2

47

14.4

44.9

22.2

NA

NA

71.6

26.8

7.8

0

8.7

0

54.2

NA

MUC5AC

84.6

86.5

75.5

55

85.7

71.4

88

6

89.5

91.7

74.8

91.7

76.9

NA

MUC6

49.7

11.2

58.3

13.9

NA

NA

NA

NA

75

NA

55.6

0

11.1

0

DPC4

93.3

98

88.6

87.5

76

NA

80

NA

57.7

47.4

60.3

47.4

96.2

NA

CEA

59

4.6

61.2

4.6

100

NA

89.9

41.5

77.8

NA

77.8

NA

71.4

NA

PAX8

36

9

33.2

8.3

4.6

5.6

0

NA

0

NA

4.2

NA

0

NA

ER

7.9

NA

9.2

NA

6.7

NA

0

NA

0

NA

0

NA

0

NA

PR

9

2.8

8.9

2.8

14.3

NA

0

NA

NA

NA

0

NA

0

NA

CA125

23.7

NA

5.5

NA

0

NA

10.8

0

0

NA

50

NA

0

NA

AMACR

67.2

55.2

67.2

55.2

NA

NA

48.2

34.1

NA

NA

NA

NA

NA

NA

CK19

80

NA

80

NA

NA

NA

40

NA

100

NA

100

NA

NA

NA

villin

41

4.8

NA

NA

95

NA

100

NA

NA

NA

NA

NA

NA

NA

POF1B

21.7

NA

NA

NA

NA

NA

36.4

NA

NA

NA

46.7

NA

46.7

NA

CA19–9

77.6

NA

77.3

NA

NA

NA

60

NA

100

NA

100

NA

NA

NA

  1. For some antibodies the % of 3+ cases is higher than % of all cases. This is due to the fact that the number of 3+ cases was calculated only from the studies in which the semiquantitative IHC results were reported
  2. NA not available; MC mucinous ovarian carcinoma; APE appendix; CRC colorectal
  3. Antibodies: SATB2 AT-rich sequence-binding protein 2; CDX2 homeobox protein CDX-2; CK7 cytokeratin 7; CK20 cytokeratin 20, MUC1 mucin 1 (also called EMA - epithelial membrane antigen); MUC2 mucin 2; MUC5AC mucin 5 AC; MUC6 mucin 6; DPC4 deleted in pancreatic cancer 4 (also called SMAD4 - SMAD family member 4); CEA carcinoembryonic antigen; PAX8 paired box gene 8; ER estrogen receptor, PR progesterone receptor; CA125 cancer antigen 125 (also called MUC16 - mucin 16); AMACR alpha-methylacyl-CoA racemase; CK19 cytokeratin 19; POF1B premature ovarian failure 1B; CA19–9 carbohydrate antigen 19–9